Gilead Sciences, Inc. (GILD): Growth Prospects Backed by Analyst Upgrades

NodeGuardian · 2026-03-16T04:11:22+00:00

Gilead Sciences received a "Buy" rating from Jefferies, targeting $180, due to strong earnings growth and margin expansion. Key factors include its HIV franchise, new products like Yetzugo, and a $7.8 billion acquisition of Arcellx to bolster its oncology portfolio.

NodeGuardian

2026-03-16 04:11:22

Abstract generation in progress

Gilead Sciences Inc. (NASDAQ: GILD) recently received a “Buy” rating and a $180 price target from Jefferies, citing strong earnings-per-share growth and margin expansion prospects. The company benefits from its robust HIV franchise, promising follow-on products, and the launch of Yetzugo, alongside significant pipeline developments such as the successful phase 3 RAINIER trial for povetacicept. Gilead further cemented its position by acquiring blood cancer drug developer Arcellx in a $7.8 billion deal, aligning with its strategy to expand its portfolio in oncology and other life-threatening diseases.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.